Effects of GYKI 52466 on Early Vasospasm in Rats

Colak A., Soy O., Karaoglan A., Akdemir O., Kokturk S., Sagmanligil A., ...Daha Fazla

CENTRAL EUROPEAN NEUROSURGERY, cilt.70, sa.4, ss.187-194, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1055/s-0029-1202357
  • Dergi Adı: CENTRAL EUROPEAN NEUROSURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.187-194
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Objective: The pathogenesis and treatment of cerebral vasospasm (CV) after subarachnoid hemorrhage (SAH) remains a matter of discussion. The authors investigated the efficacy of GYKI 52466, a 2,3-benzodiazepine that is a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptor antagonist, in a rat femoral artery vasospasm model.